Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Lu-177 DOTATATE in NETs
NCT03629847Phase 2Unknown
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- Dec 2012
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in Neuroendocrine Neoplasm (NEN), sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoint: Incidence of treatment related adverse events at 3 years. Status: unknown.
02
Drugs
everolimus
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03629847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629847.